Pure Global AI
NCT06238401Not yet recruiting

Study of ACR246 in Advanced Solid Tumors

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase I/II.a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., LtdPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
ACR246 for injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hangzhou Adcoris Biopharmacy Co., Ltd
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2024
End date
Jan 01, 2026
Enrollment
77 participants
Primary outcome

Safety and tolerability:

Summary

The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with
 advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended
 dose (RP2D) of ACR246.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06238401
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06238401 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hangzhou Adcoris Biopharmacy Co., Ltd and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 77 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.